Gout is a chronic disease caused by the deposition of monosodium urate (MSU) crystals in joints. It typically presents as an acute, self-limiting inflammatory monoarthritis that affects the joints of the lower limb. Various symptoms of Gout include intense joint pain, joint swelling, stiffness, tenderness, even to light touch, such as from a bedsheet, heat in the affected area, and joint redness.
Currently, there are more than 40 drugs in the Gout pipeline, which are under different phases of development.
DelveInsight brings into notice the current Gout marketspace including market trends, epidemiology, diagnosis, and current as well as anticipated treatment prospects encapsulated inside this newsletter. Track the recent happenings, ongoing research & development, significant pharmaceutical companies involved in the Gout market, top-notch collaborations in the space, licensing & funding details, and major breakthroughs in the Gout market landscape.
Explore more about the Gout pipeline therapies, clinical trials, deals & tie-ups, upcoming world-class conferences, and get fresh updates in the Gout market. Discover the newsletter directly mailed to your email box by filling up a simple form towards your right. Join our Newsletter series and get rich insights delivered every week to you.
Subscribe to our mailing list and stay informed about all the latest developments in the Arthritis therapeutic market.
Know more about What's covered:
- Indication Overview
- Gout Epidemiological Trends
- Current Gout Treatment Regimen
- R&D in the field
- Top Conferences
- News Flash
- Recent Research Activities
- Support from International Organizations
- Gout Market Insights
- Gout Market Dynamics
- Collaborations & Fundings